Filtered By:
Vaccination: Meningitis Vaccine
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 2891 results found since Jan 2013.
Addressing racial inequality and its effects on vaccination rate: A trial comparing a pharmacist and peer educational program (MOTIVATE) in diverse older adults
CONCLUSIONS: Both interventions significantly improved knowledge and trust toward vaccination and retained their effect 1 month after the program. The 2 effective community-based education models should be expanded to ensure timely and trusted information is available to educate older adults about vaccine-preventable diseases. Further research is encouraged to assess the long-term cost-effectiveness of these models' utilization on a larger scale. DISCLOSURES: Dr Schafer is an employee of Merck; however, at the time of the project, he was a professor at Thomas Jefferson University. The other authors have no conflicts of int...
Source: Herpes - July 31, 2023 Category: Infectious Diseases Authors: Katherine M Prioli Ayse Akincigil Tarlan Namvar Jocelyn Mitchell-Williams Jason J Schafer Renee C Cunningham Lynn Fields-Harris Megan McCoy Ronald Vertsman Ashley Guesnier Laura T Pizzi Source Type: research
Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada
The objective was to estimate PCV13 effectiveness to prevent serotype 3 invasive pneumococcal disease in children aged less than 5 years, using 2010-2018 mandatory notification and laboratory surveillance data, an indirect cohort design and multivariate logistic regression models. A total of 29 cases of serotype 3 and 290 non-vaccine serotype cases as controls were analysed. Overall vaccine effectiveness (≥1 dose) was estimated at 59% [-39% to 88%]. During the first year after the last dose effectivness was 88% [47% to 97%] whereas no protection was observed thereafter. There was no trend towards increased effectiveness ...
Source: Vaccine - July 31, 2023 Category: Allergy & Immunology Authors: Genevi ève Deceuninck Nicholas Brousseau Brigitte Lefebvre Caroline Quach Bruce Tapiero Yen-Giang Bui Micha ël Desjardins Philippe De Wals Source Type: research
Spread of multidrug resistance in non-PCV13/PCV20 serotypes of Streptococcus pneumoniae: A cross-sectional study ten years after the introduction of pneumococcal conjugate vaccine in Japan
J Microbiol Immunol Infect. 2023 Jul 20:S1684-1182(23)00123-8. doi: 10.1016/j.jmii.2023.07.004. Online ahead of print.ABSTRACTTen years after the introduction of the pneumococcal conjugate vaccine (PCV) in Japan, the prevalence rates of non-PCV13 and non-PCV20 serotypes among pediatric pneumococcal isolates were 94.0% and 73.7%, respectively. The predominant non-PCV13/PCV20 serotypes (15A, 35B, and 23A) were mostly multidrug-resistant (≥80.5%), exhibiting non-susceptibility to penicillin.PMID:37517964 | DOI:10.1016/j.jmii.2023.07.004
Source: Journal of Microbiology, Immunology, and Infection - July 30, 2023 Category: Microbiology Authors: Mitsuyo Kawaguchiya Noriko Urushibara Meiji Soe Aung Nobuhide Ohashi Rika Takamatsu Sho Tsutida Masahiko Ito Nobumichi Kobayashi Source Type: research
Use of Information and Communication Technology Strategies to Increase Vaccination Coverage in Older Adults: A Systematic Review
CONCLUSIONS: Prevention programs using ICT tools could be effective in promoting immunizations among older adults.PMID:37515089 | DOI:10.3390/vaccines11071274
Source: Herpes - July 29, 2023 Category: Infectious Diseases Authors: Alessandra Buja Giulia Grotto Mustapha Taha Silvia Cocchio Vincenzo Baldo Source Type: research
Temporally Associated Invasive Pneumococcal Disease and SARS-CoV-2 Infection, Alaska, USA, 2020-2021
We described the epidemiology and clinical course of patients who had invasive pneumococcal disease (IPD) and temporally associated SARS-CoV-2 infections in Alaska, USA, during January 1, 2020-December 23, 2021. Of 271 patients who had laboratory-confirmed IPD, 55 (20%) had a positive SARS-CoV-2 test result. We observed no major differences in age, race, sex, or underlying medical conditions among IPD patients with and without SARS-CoV-2. However, a larger proportion of IPD patients with SARS-CoV-2 died (16%, n = 9) than for those with IPD alone (4%, n = 9) (p<0.01). IPD patients with SARS-CoV-2 were also more likely to...
Source: Emerging Infectious Diseases - July 28, 2023 Category: Infectious Diseases Authors: Katherine Newell Marc Fischer Stephanie Massey Laurie Orell Jonathan Steinberg Megan Tompkins Louisa Castrodale Joseph McLaughlin Source Type: research
Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study
CONCLUSION: In this high-risk population, no statistically significant incremental effect of a PPV23 booster at 18-30 months was observed against hospitalised all-cause pneumonia or the more specific outcome of presumptive pneumococcal pneumonia. Confounding by indication may explain the slight trend towards an increased risk against all-cause pneumonia. Larger studies with better control of confounding are needed to further inform PPV23 vaccination.PMID:37507273 | DOI:10.1016/j.vaccine.2023.07.042
Source: Vaccine - July 28, 2023 Category: Allergy & Immunology Authors: Alamgir Kabir Deborah Randall Anthony T Newall Hannah C Moore Sanjay Jayasinghe Parveen Fathima Bette Liu Peter McIntyre Heather F Gidding Source Type: research
Temporally Associated Invasive Pneumococcal Disease and SARS-CoV-2 Infection, Alaska, USA, 2020-2021
We described the epidemiology and clinical course of patients who had invasive pneumococcal disease (IPD) and temporally associated SARS-CoV-2 infections in Alaska, USA, during January 1, 2020-December 23, 2021. Of 271 patients who had laboratory-confirmed IPD, 55 (20%) had a positive SARS-CoV-2 test result. We observed no major differences in age, race, sex, or underlying medical conditions among IPD patients with and without SARS-CoV-2. However, a larger proportion of IPD patients with SARS-CoV-2 died (16%, n = 9) than for those with IPD alone (4%, n = 9) (p<0.01). IPD patients with SARS-CoV-2 were also more likely to...
Source: Emerging Infectious Diseases - July 28, 2023 Category: Infectious Diseases Authors: Katherine Newell Marc Fischer Stephanie Massey Laurie Orell Jonathan Steinberg Megan Tompkins Louisa Castrodale Joseph McLaughlin Source Type: research
Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study
CONCLUSION: In this high-risk population, no statistically significant incremental effect of a PPV23 booster at 18-30 months was observed against hospitalised all-cause pneumonia or the more specific outcome of presumptive pneumococcal pneumonia. Confounding by indication may explain the slight trend towards an increased risk against all-cause pneumonia. Larger studies with better control of confounding are needed to further inform PPV23 vaccination.PMID:37507273 | DOI:10.1016/j.vaccine.2023.07.042
Source: Vaccine - July 28, 2023 Category: Allergy & Immunology Authors: Alamgir Kabir Deborah Randall Anthony T Newall Hannah C Moore Sanjay Jayasinghe Parveen Fathima Bette Liu Peter McIntyre Heather F Gidding Source Type: research
Temporally Associated Invasive Pneumococcal Disease and SARS-CoV-2 Infection, Alaska, USA, 2020-2021
We described the epidemiology and clinical course of patients who had invasive pneumococcal disease (IPD) and temporally associated SARS-CoV-2 infections in Alaska, USA, during January 1, 2020-December 23, 2021. Of 271 patients who had laboratory-confirmed IPD, 55 (20%) had a positive SARS-CoV-2 test result. We observed no major differences in age, race, sex, or underlying medical conditions among IPD patients with and without SARS-CoV-2. However, a larger proportion of IPD patients with SARS-CoV-2 died (16%, n = 9) than for those with IPD alone (4%, n = 9) (p<0.01). IPD patients with SARS-CoV-2 were also more likely to...
Source: Emerging Infectious Diseases - July 28, 2023 Category: Infectious Diseases Authors: Katherine Newell Marc Fischer Stephanie Massey Laurie Orell Jonathan Steinberg Megan Tompkins Louisa Castrodale Joseph McLaughlin Source Type: research
